Finding · criterion S4

Which peptides do the telehealth services actually sell?

Of the 167 telehealth services in the ledger, 157 list a GLP-1 drug and 130 list at least one other peptide or NAD+. The second list is led by NAD+ (125), Sermorelin (114), Glutathione (86). Sermorelin, listed by 114, has had no approved product since 2009.

• 167telehealth services in the ledger
• 130list a peptide other than a GLP-1, or NAD+
• 12list a molecule whose compounding nomination was withdrawn, or that cannot be compounded
• 11sites call an unapproved product FDA-approved

Every molecule, who lists it, and what FDA says

Each row counts the telehealth records whose own product list names the molecule, and how many of those pass the first four criteria of the Standard: a named prescriber (S1), an order path that stops at a medical intake (S2), a named filling pharmacy (S3) and a compounding disclosure (S4). The status column quotes FDA's own pages.

What “prescribed” looks like on the page

167 of the 167 telehealth records name a prescriber, which is close to the floor for being a telehealth service at all. The criteria that separate them come after. Of the 130 services listing a peptide beyond the GLP-1s, 66 name the pharmacy that fills the order, and 99 say on their own pages that a compounded drug is not FDA-approved. The rest leave a reader to assume where the vial comes from and what status it has.

Listings outside the approved and Category 1 set

12 services list a molecule that has no approved product and whose nomination for 503A compounding was withdrawn, or that FDA says cannot be compounded at all. This is a fact about the listing, recorded as the seller printed it. It is not a finding that any order was filled, and the page states no view on what a pharmacy may lawfully make.

Pages that call an unapproved product FDA-approved

The telehealth sites in the ledger were read for the words FDA-approved beside a product they sell. These sentences were on the page in September 2026. Sermorelin has had no approved product since FDA withdrew the approval of Geref, effective June 18, 2009. The only approved bremelanotide is Vyleesi, an autoinjector for premenopausal women; a compounded PT-141 injection, nasal spray or troche is not that product. A compounded semaglutide or tirzepatide is not Ozempic, Wegovy, Mounjaro or Zepbound.

• LaSara Medical Group, on the page selling sermorelin: Yes, Sermorelin is FDA-approved for growth hormone stimulation and has been widely studied for its safety and effectiveness.
• LaSara Medical Group, on the page selling sermorelin: Yes! Sermorelin is clinically studied and FDA-approved for stimulating natural growth hormone production.
• LaSara Medical Group, on the page selling compounded PT-141: Yes! Bremelanotide has been clinically tested and is FDA-approved for female sexual health.
• Direct Meds, on the page selling compounded tirzepatide: FDA approved for long term weight loss
• DudeMeds, on the page selling semaglutide: Semaglutide is an FDA-approved medication shown to significantly aid weight loss by reducing appetite and promoting a feeling of fullness.
• Arc-1, on the page selling compounded semaglutide: This FDA-approved drug is now recognized for its effectiveness in promoting significant weight reduction
• FormBlends, on the page selling compounded PT-141: FDA-approved for women with low sexual desire.
• Regenics, on the page selling compounded PT-141: PT-141 is FDA-approved specifically for premenopausal women with hypoactive sexual desire disorder (HSDD).
• Rx Peps Direct, on its answers page, about sermorelin and tesamorelin: Some peptides Rx Peps Direct prescribes are FDA-approved branded drugs (sermorelin, tesamorelin) prescribed in compounded form for individualized dosing.
• Defy Medical, in an article about sermorelin: Sermorelin is an FDA-approved secretagogue that stimulates the pituitary gland to release Human Growth Hormone (hGH).
• Hone Health, in an article about sermorelin: Sermorelin is FDA-approved to treat growth hormone deficiency in children.
• ReadyRx, in an article about sermorelin: Sermorelin is FDA-approved and widely used in longevity and hormone optimization programs under physician guidance.
• Tyde Wellness, in an article about sermorelin: Sermorelin is FDA approved for treating growth hormone deficiency in children, but it is also used for adults, particularly women experiencing hormonal fluctuations during perimenopause and menopause. The same article also says It’s crucial to note that Sermorelin isn’t currently FDA-approved for adult use.

A claim on a page that sells the product fails S4 on that record, because it contradicts the disclosure the criterion asks for. The same sentence in an article, on a site whose product pages carry the disclosure, is quoted in the record and does not change the disposition.

What this does not say

It does not say any service prescribes inappropriately, and it does not rank the services. A molecule on FDA's Category 1 list can be compounded for an individual patient under section 503A while FDA evaluates it; a molecule whose nomination was withdrawn sits on no interim list, and FDA's pages say what that means. Each record carries its own reading date and its eight dispositions.

Sources

• FDA, Semaglutide
• FDA, Tirzepatide
• FDA, Liraglutide
• FDA, PT-141
• FDA, Tesamorelin
• FDA, Sermorelin
• FDA, NAD+
• FDA, BPC-157
• FDA, Retatrutide
• LaSara Medical Group, its product page
• LaSara Medical Group, its product page
• LaSara Medical Group, its product page
• Direct Meds, its product page
• DudeMeds, its product page
• Arc-1, its product page
• FormBlends, its product page
• Regenics, its product page
• Rx Peps Direct, its answers page
• Defy Medical, an article on its own site
• Hone Health, an article on its own site
• ReadyRx, an article on its own site
• Tyde Wellness, an article on its own site

Counts are computed at build time from the ledger against Standard v1.1. FDA pages and seller pages were read in September 2026.

Counts are generated from the ledger at build time, so this page cannot drift from the records it summarizes. Method and null semantics: how checks are performed. This page ranks nothing, recommends nothing, and carries no partner link.

Related findings

All 19 findings →